Carton L, Icick R, Weibel S, Dematteis M, Kammerer E, Batisse A, Rolland B. What is the potential for abuse of lisdexamfetamine in adults? A preclinical and clinical literature review and expert opinion. Expert Rev Clin Pharmacol. 2022 Aug 18:1-5. doi: 10.1080/17512433.2022.2112950. Epub ahead of print. PMID: 35959655.
Goncalves R, Peyré A, Castaing N, Beeken T, Olivier S, Combe P, Miremont-Salamé G, Titier K, Molimard M, Daveluy A. Minors and young adult’s hospitalizations after « chimique » consumption in Mayotte Island: Which substances are involved? Therapie. 2022 Aug 1:S0040-5957(22)00124-X. doi: 10.1016/j.therap.2022.07.007. Epub ahead of print. PMID: 36064627.
Laforgue EJ, Rousselet M, Claudon A, Aquizerate A, Jolliet P, Istvan M, Victorri-Vigneau C. Did the New French Regulation of Zolpidem Decrease the Problematic Consumption of Zolpidem? A Field Study among Users. Int J Environ Res Public Health. 2022 Jul 22;19(15):8920. doi: 10.3390/ijerph19158920. PMID: 35897285; PMCID: PMC9331950.
Eiden C, Roy S, Malafaye N, Lehmann M, Peyrière H. Ten-year trends in hospitalizations related to cocaine abuse in France. Fundam Clin Pharmacol. 2022 Jul 8. doi: 10.1111/fcp.12815. Epub ahead of print. PMID: 35801616.
Ten-year trends in hospitalizations related to cocaine abuse in France. Lire la suite »
Dumoulin C, Ong N, Ramaroson H, Létinier L, Miremont-Salamé G, Gilleron V, Daveluy A, Perino J. Hospitalisations après consommation de substances psychoactives pendant la pandémie de Covid-19 [Hospitalizations after substance use during the COVID-19 pandemic]. Therapie. 2022 Jun 30:S0040-5957(22)00108-1. French. doi: 10.1016/j.therap.2022.06.003. Epub ahead of print. PMID: 35908997; PMCID: PMC9329723.
Revol B, Lapeyre-Mestre M, Fouilhé Sam-Laï N, Jouanjus E. Association between NMDAR antagonists, drug abuse and dependence: A disproportionality analysis from the WHO pharmacovigilance database. Br J Clin Pharmacol. 2022 Jun 4. doi: 10.1111/bcp.15430. Epub ahead of print. PMID: 35665950.
Roy S, Charreteur R, Peries M, Kheloufi F, Eiden C, Nagot N, Donnadieu-Rigole H, Micallef J, Peyrière H. Abuse and misuse of second-generation antipsychotics: an analysis using VigiBase TM , the World Health Organisation pharmacovigilance database. Br J Clin Pharmacol. 2022 May 27. doi: 10.1111/bcp.15420. Epub ahead of print. PMID: 35633029.
Guerra C, Soeiro T, Lacroix C, Jouve E, Micallef J, Frauger E. Augmentation de l’abus de méthylphénidate : repérage et profils sur 13 années [Increasing methylphenidate abuse: Tracking and profiles during 13-years]. Therapie. 2022 Apr 26:S0040-5957(22)00066-X. French. doi: 10.1016/j.therap.2022.03.006. Epub ahead of print. PMID: 35599193.
Augmentation de l’abus de méthylphénidate : repérage et profils sur 13 années Lire la suite »
Largeau B, Karam A, Potey C, Caous AS, Tard C, Carton L, Kuchcinski G, Gautier S, Deheul S, Bordet R. Myeloneuropathy induced by recreational nitrous oxide use with variable exposure levels. Eur J Neurol. 2022 Apr 23. doi: 10.1111/ene.15370. Epub ahead of print. PMID: 35460312.
Laforgue EJ, Istvan M, Schreck B, Mainguy M, Jolliet P, Grall-Bronnec M, Victorri-Vigneau C. Perception of the Regulatory Change for Zolpidem Prescription by French General Practitioners and Its Relation to Prescription Behavior. J Clin Med. 2022 Apr 13;11(8):2176. doi: 10.3390/jcm11082176. PMID: 35456269; PMCID: PMC9032177.